期刊
CANCER JOURNAL
卷 22, 期 2, 页码 68-72出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0000000000000185
关键词
Biomarkers; cancer; driver mutations; immune checkpoint therapy
类别
资金
- SU2C-CRI Dream Team Cancer Immunotherapy Grant
- PCF Challenge Grant in Immunology
- NCI/NIH [1-R01 CA1633793-01]
- Cancer Prevention Research in Texas [RP120108]
Immune checkpoint therapy has started a revolution in the field of oncology. The concept that the immune systemplays a critical role in antitumor responses, which has been around for decades, has finally been proven and firmly established with elegant preclinical studies and dramatic clinical responses in patients as a result of antibodies that block inhibitory T-cell pathways. However, the clinical responses being achieved are only in a subset of patients, and more work is needed to provide a better understanding of the mechanisms that elicit tumor rejection, which will enable identification of appropriate biomarkers, reveal new targets, provide data to guide combination studies, and eventually dictate a platform that allows more patients to derive clinical benefit, including cures, with immune checkpoint therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据